Tags

Type your tag names separated by a space and hit enter

omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study.
Am J Psychiatry 2003; 160(1):167-9AJ

Abstract

OBJECTIVE

The purpose of this study was to compare the efficacy of ethyl-eicosapentaenoic acid (E-EPA) and placebo in the treatment of female subjects with borderline personality disorder.

METHOD

The authors conducted an 8-week, placebo-controlled, double-blind study of E-EPA in 30 female subjects meeting Revised Diagnostic Interview for Borderlines and DSM-IV criteria for borderline personality disorder.

RESULTS

Twenty subjects were randomly assigned to 1 g of E-EPA; 10 subjects were given placebo. Ninety percent of those in both groups completed all 8 weeks of the trial. Analyses that used random-effects regression modeling and controlled for baseline severity showed E-EPA to be superior to placebo in diminishing aggression as well as the severity of depressive symptoms.

CONCLUSIONS

The results of this study suggest that E-EPA may be a safe and effective form of monotherapy for women with moderately severe borderline personality disorder.

Authors+Show Affiliations

Laboratory for the Study of Adult Development, McLean Hospital, Belmont, MA 02478, USA. zanarini@mclean.harvard.eduNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12505817

Citation

Zanarini, Mary C., and Frances R. Frankenburg. "Omega-3 Fatty Acid Treatment of Women With Borderline Personality Disorder: a Double-blind, Placebo-controlled Pilot Study." The American Journal of Psychiatry, vol. 160, no. 1, 2003, pp. 167-9.
Zanarini MC, Frankenburg FR. Omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 2003;160(1):167-9.
Zanarini, M. C., & Frankenburg, F. R. (2003). Omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. The American Journal of Psychiatry, 160(1), pp. 167-9.
Zanarini MC, Frankenburg FR. Omega-3 Fatty Acid Treatment of Women With Borderline Personality Disorder: a Double-blind, Placebo-controlled Pilot Study. Am J Psychiatry. 2003;160(1):167-9. PubMed PMID: 12505817.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. AU - Zanarini,Mary C, AU - Frankenburg,Frances R, PY - 2002/12/31/pubmed PY - 2003/1/31/medline PY - 2002/12/31/entrez SP - 167 EP - 9 JF - The American journal of psychiatry JO - Am J Psychiatry VL - 160 IS - 1 N2 - OBJECTIVE: The purpose of this study was to compare the efficacy of ethyl-eicosapentaenoic acid (E-EPA) and placebo in the treatment of female subjects with borderline personality disorder. METHOD: The authors conducted an 8-week, placebo-controlled, double-blind study of E-EPA in 30 female subjects meeting Revised Diagnostic Interview for Borderlines and DSM-IV criteria for borderline personality disorder. RESULTS: Twenty subjects were randomly assigned to 1 g of E-EPA; 10 subjects were given placebo. Ninety percent of those in both groups completed all 8 weeks of the trial. Analyses that used random-effects regression modeling and controlled for baseline severity showed E-EPA to be superior to placebo in diminishing aggression as well as the severity of depressive symptoms. CONCLUSIONS: The results of this study suggest that E-EPA may be a safe and effective form of monotherapy for women with moderately severe borderline personality disorder. SN - 0002-953X UR - https://www.unboundmedicine.com/medline/citation/12505817/omega_3_Fatty_acid_treatment_of_women_with_borderline_personality_disorder:_a_double_blind_placebo_controlled_pilot_study_ L2 - https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.160.1.167?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -